Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis

被引：0
|
作者：
Hameed, M. [1 ]
Exarchou, S. [1 ]
Eberhard, A. [1 ]
Sharma, A. [1 ]
Bergstrom, U. [1 ]
Einarsson, J. [2 ]
Turesson, C. [1 ]
机构：
[1] Lund Univ, Rheumatol, Dept Clin Sci, Malmo, Sweden
[2] Lund Univ, Rheumatol, Dept Clin Sci, Malmo, Sweden
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2023年 / 52卷
关键词：
Rheumatoid arthritis; bDMARDs; Predictors;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP08
引用
收藏
页码：67 / 68
页数：2
相关论文
共 50 条
  • [31] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
  • [32] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [33] PREDICTIVE FACTORS FOR SUCCESSFUL BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS DOSE TAPERING IN RHEUMATOID ARTHRITIS
    Loh, Min Yi
    Jones, Claire J.
    Peall, Adrian
    Trickey, Jeanette
    RHEUMATOLOGY, 2023, 62
  • [34] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Fleischmann, Roy
    CLINICAL RHEUMATOLOGY, 2021, 40 (11) : 4369 - 4372
  • [35] Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis
    Sendaydiego, Xavier
    Gold, Laura
    Wysham, K.
    Liew, Jean
    Dubreuil, Maureen
    Andrews, James
    Reid, Pankti
    Liew, David
    Goulabchand, Radjiv
    Singh, Abha
    Hughes, Grant
    Pioro, Mathilde
    Sparks, Jeffrey
    Jarvik, Jeffrey
    Singh, Siddharth
    Singh, Namrata
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 848 - 850
  • [36] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    Clinical Rheumatology, 2020, 39 : 207 - 216
  • [37] Two Cases of High Tibial Osteotomy in Patients with Rheumatoid Arthritis Treated with Biologic Disease-modifying Anti-rheumatic Drugs
    Takahara, Yasuhiro
    Nishida, Keiichiro
    Nakashima, Hirotaka
    Ochi, Nobuaki
    Uchida, Yoichiro
    Kato, Hisayoshi
    Itani, Satoru
    Nakamura, Makoto
    Iwasaki, Yuichi
    Tsujimura, Yoshitaka
    ACTA MEDICA OKAYAMA, 2019, 73 (06) : 537 - 542
  • [38] Use of disease-modifying anti-rheumatic drugs and cardiovascular events in patients with rheumatoid arthritis
    Kaminski, Matthew
    Shishehbor, Mehdi H.
    Gutierrez, Antonio
    Amini, Mohammad R.
    Coats, Walter
    Moghbelli, Meisam
    Askari, Arman T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A370 - A370
  • [39] Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis
    Cannon, Grant W.
    Teng, Chia-Chen
    He, Tao
    Leng, Jianwei
    Lu, Chao-Chin
    Tang, Derek
    Shah, Neel
    Harrison, David J.
    Sauer, Brian
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S213 - S213
  • [40] Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients
    Convertino, Irma
    Cazzato, Massimiliano
    Tillati, Silvia
    Giometto, Sabrina
    Gini, Rosa
    Valdiserra, Giulia
    Cappello, Emiliano
    Ferraro, Sara
    Bonaso, Marco
    Bartolini, Claudia C.
    Paoletti, Olga
    Lorenzoni, Valentina
    Filippi, Matteo
    Turchetti, Giuseppe
    Cristofano, Michele
    Blandizzi, Corrado
    Mosca, Marta
    Lucenteforte, Ersilia
    Tuccori, Marco
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 488 - 489
12345